In this edition, immunotherapy improves survival rates of infants with leukemia; extreme poverty linked to higher risk for relapse among children with ALL; FDA approves allogeneic cell therapy and more.
Read the full coverage here:
Addition of immunotherapy to chemotherapy improves survival rates of infants with leukemia
Extreme poverty linked to nearly twofold higher risk for relapse among children with ALL
FDA approves allogeneic cell therapy Omisirge for patients with blood cancers
Vaping linked to cancer-related cognitive impairment among young adult cancer survivors
Intervention reduces financial toxicity among people with blood cancers
References:
Healio Interview
Ng DQ, et al. JCO Oncol Pract. 2023;doi:10.1200/op.22.00458.
van der Sluis IM, et al. N Eng J Med. 2023;doi:10.1056/NEJMoa2214171.
